Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

about

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

Item

http://www.wikidata.org/entity/Q55417125

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Systemic treatment of advanced ...... ontroversies and perspectives.

@en

Systemic treatment of advanced ...... ontroversies and perspectives.

@nl

type

Item

label

Systemic treatment of advanced ...... ontroversies and perspectives.

@en

Systemic treatment of advanced ...... ontroversies and perspectives.

@nl

prefLabel

Systemic treatment of advanced ...... ontroversies and perspectives.

@en

Systemic treatment of advanced ...... ontroversies and perspectives.

@nl

P1476

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives

@en

P2093

Andreas Tiefenbacher

http://www.w3.org/2001/XMLSchema#string

Robert Pirker

http://www.w3.org/2001/XMLSchema#string

P2860

Nedaplatin: a cisplatin derivative in cancer chemotherapy

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?

The next-generation ALK inhibitors.

P304

112-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12254-018-0408-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29983826

http://www.w3.org/2001/XMLSchema#string

P932

6006273

http://www.w3.org/2001/XMLSchema#string